Form 4: iRhythm Technologies Executive Chad Patterson Reports Stock Transactions

Chief Commercial Officer Chad Patterson of iRhythm Technologies reports the acquisition of 280 shares through an employee stock purchase plan and the sale of 3,012 shares to cover tax obligations.

Summary

• Chad Patterson, Chief Commercial Officer of iRhythm Technologies, filed a Form 4 detailing changes in beneficial ownership.
• On May 31, 2024, Patterson acquired 280 shares of common stock at $74.98 per share through the company's employee stock purchase plan.
• On August 2, 2024, Patterson sold 3,012 shares at $74.66 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units.
• Following these transactions, Patterson directly owns 37,133 shares of iRhythm Technologies common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document simply reports stock transactions. There is no indication of positive or negative sentiment towards the company's performance.

Positives

• The acquisition of shares through the employee stock purchase plan indicates Patterson's investment in the company's future.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces Patterson's holdings.

Risks

• There are no specific risks highlighted in this document, as it primarily reports stock transactions.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's investment activities in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for executives in publicly traded companies like iRhythm Technologies.
• The transactions reported are typical for executives who participate in employee stock purchase plans and receive restricted stock units, similar to practices at companies like Medtronic or Boston Scientific.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting or increasing the number of outstanding shares.

Key Dates